# OnCo record pegvorhyaluronidase-alfa (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pegvorhyaluronidase-alfa/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pegvorhyaluronidase-alfa" ;
  schema:name "Pegvorhyaluronidase alfa"@en ;
  schema:alternateName "PEGPH20"@en, "PEGylated recombinant human hyaluronidase"@en ;
  schema:description "PEGPH20 was designed to break down the hyaluronan that stiffens pancreatic tumours and let chemotherapy in; in the phase 3 HALO-301 trial it raised response rates but not survival, and Halozyme stopped developing it in 2019."@en ;
  schema:url <https://onco.cc/drugs/pegvorhyaluronidase-alfa/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.00590>, <https://clinicaltrials.gov/study/NCT02715804> ;
  onco:status "negative" ;
  onco:modality "PEGylated recombinant hyaluronidase (stroma-degrading enzyme)" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:companies <https://onco.cc/companies/halozyme/> ;
  onco:terms <https://onco.cc/terms/desmoplasia/>, <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  onco:trials <https://onco.cc/trials/halo-301/> .